The most common childhood cancer is acute lymphoblastic leukemia (ALL). Chemotherapy-associated hematological toxicity is well-known; however, there are few studies on hematologic toxicity incidence in children with ALL. We investigated the severity and incidence of hematologic toxicity during intense chemotherapy processes in children treated with ALL IC-BFM 2009 protocol. The study included 41 leukemic children in standard (SR) and intermediate risk (IR) groups treated between 2011 and 2015. During the induction period, the incidence of grade 4 toxicity in neutrophil count was 60%; the incidence of grade ≥ 3 toxicity in hemoglobin level was 34%; and the incidence of grade ≥ 3 toxicity in the platelet count was 51%. Deep neutropenia duration was 36.6 ± 12.7 (18 -68) days during the induction. 53% of the febrile neutropenic (FEN) episodes developed during the induction period. There were no statistical differences between SR and IR risk groups with respect to hemogram values deep neutropenia duration and the number of FEN episodes (p > 0.05, all). There was a positive correlation between the number of FEN episodes and duration of neutropenia. During the induction, the mean neutrophil count remained between 0.5 -1 × 10 9 /L. FEN episodes most commonly developed during the induction phase.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and represents 30% of all childhood cancers [1] . Survival rates have dramatically improved since 1980 and today, the five-year survival rates are predicted to be around 80% [2] . This success could be achieved by high-dose chemotherapy and supportive treatments. However, chemotherapy-associated toxicity remains as a problematic issue. Neutropenia is the most common hematologic toxicity and leads to life-threatening infections. It is of importance for each center to demonstrate the causative agent of neutropenic fever and the susceptibility of antibiotics in fighting with infections. We believe that knowing the periods of severe neutropenia development and intensification of neutropenic episodes could be important in reducing infection-related losses.
Anemia and thrombocytopenia frequently occur as a side effect of cytotoxic chemotherapy and blood product transfusions are needed during treatment.
Blood transfusions involve several risks including infection transmission, allergic
reactions, immunosensitivity, iron overload, graft versus host disease. Being aware of the extent of transfusion administered to patients may be interesting with respect to reminding the extent of the risks confronted by the patients.
While chemotherapy-associated hematologic toxicity is a well-known topic, there are a few studies evaluating chemotherapy-associated hematologic toxicity [3] - [8] .
In this trial, we investigated the level of severe neutropenia, anemia, thrombocytopenia incidence, deep neutropenia duration, incidence of febrile neutropenic episodes, and the extent of transfusion during intense chemotherapy in leukemic children, treated with ALL IC-BFM 2009 protocol.
Material and Methods
Forty-one children (2 -17 years old) with a diagnosis of intermediate or standard risk ALL who were treated with chemotherapy between April 2011 and June 2015 whose files were complete, were included in this study. Three relapsed patients were excluded, due to they were treated with a different protocol (ALL-REZ BFM 2002) and 3 children with high risk ALL were excluded because their consolidation treatment is different from children in the SR and IR risk groups.
The patient data were obtained retrospectively from the hospital's information system. Demographic features, risk groups, hemogram data obtained during treatment, number of febrile neutropenic episodes, the quantities of erythrocyte, . In addition, there is no difference in the drug doses taken by the two groups. Maintenance treatment consists of only oral methotrexate and purinethol treatment. Therefore, the study assessed the induction, consolidation and re-induction phases where intense chemotherapy was administered. The drug doses, duration and the mode of administration used during the protocol are presented in Table 2 .
The level of toxicity in blood values was classified based on the Common Terminology Criteria for Adverse Events 2010 guideline [10] ( Table 3 ). The Hb, hemoglobin; ANC, absolute neutrophil count; PLT, platelet count, AST, aspartat aminotransferase; ALT, alanine aminotransferase; LLN: lower limit of normal; ULN, upper limit of normal. ment phase. Patients were divided into two groups as the SR and IR risk groups.
Hemoglobin, leukocyte, neutrophil, platelet counts, deep neutropenia duration, and the number of febrile neutropenic episodes were compared for the treatment phases of the two groups. The correlations between the absolute neutrophil count (ANC), the duration and the number of febrile neutropenic episodes were investigated.
During the protocol, the change in the ANC was converted to a graph. For this purpose, the lowest, highest and the mean ANC were used on days 1 -8, 8 -15, and 15 -33 during the induction phase, the cytarabine (ARA-C) block, and the remaining parts of the protocol.
Statistical Analyses
All analyses were performed with SPSS 21.0 statistical packaged software (SPSS for Windows 21.0; SPSS, Chicago, IL, USA). The normality of distributions was evaluated using the Kolmogorov-Smirnov test. Descriptive statistics used the mean and standard deviation (mean ± SD) for normally distributed variables, and the median and interquartile distribution range was used for other variables.
The comparisons between the SR and IR risk groups were made with the Mann Whitney U test and independent t test. In order to evaluate the correlation between the variables, Pearson correlation test was applied. P < 0.05 was considered to indicate statistical significance.
Results
A total 41 children with ALL were enrolled in this study. Thirty-eight (92%) pa- 
Discussion
The most severe hematologic toxicity of cytotoxic chemotherapy is neutropenia.
Chemotherapy predisposes the patients to infection by both suppressing the . In our trial, as could be seen in Fig.4 , the ANC decreases to the lowest values and during induction, severe neutropenia continues. Badr et al. [3] suggested that the higher neutropenia incidence during early cycles was due to more intense chemotherapy administered during induction.
In a study assessing 366 pediatric patients who received chemotherapy due to leukemia, lymphoma and solid tumors, the mean neutropenia duration was 11 days; the results showed that this time was longer during the initial chemotherapy period in ALL patients (18 days on average) [4] . Biswall et al. [16] reported that 172 febrile neutropenic attacks occurred in 112 ALL patients, consisting of children and adults and the mean neutropenia duration was 14 days. Based on the data from 81 leukemic patients consisting of adolescents and young adults from Spain, the incidence of grade 3 and 4 neutropenia was 68% during the induction period and the mean neutropenia duration was 16 (2 -41) days [17) ]. Li et al. [8] reported that the incidence of infection was 19.6% during induction and Tang et al. reported [18] a rate of 27%; Nakamura et al. [19] reported that 737 infection attacks occurred in 72 patients. In a study by Li et al. [8] , the neutropenia duration was reported as 10 days during the induction period; 50 patients had 65 infection attacks; and the frequency of infection attacks ranged between 15% and 20% in all three risk groups and there was no statistical difference. In our trial, we observed that 41 patients developed 202 neutropenic at- (Figure 3 ). In our trial, the mean deep neutropenia time was detected as 36.6 ± 12.7 days (Table 4) . We attributed the high infection incidence to the longer neutropenia duration (Figure 4 ).
Nearly all chemotherapy drugs cause myelosuppression, mucositis and nausea/vomiting. The most important toxic effect of daunorubicin is cardiotoxicity [20] . Based on the ALL IC-BFM 2009 protocol, patients in the IR risk group received daunorubicin at a dose of 120 mg/m 2 and patients in the SR risk group received at a dose of 60 mg/m 2 ( Table 2 ). Despite this, there was no difference between the two groups in leukocyte, neutrophil counts, neutropenia duration and the incidence of neutropenic fever (Table 5 , Figure 3 ). In adult AML patients receiving a higher dose of daunorubicin, there was no difference with respect to neutrophil recovery time, antibiotic use time and transfusion amounts compared to those receiving a standard dose [21] . This suggested that a higher dose of daunorubicin did not increase hematologic toxicity.
In our study, there was no difference between the SR and IR groups with respect to febrile neutropenic episodes incidence. In the previous two studies, no difference was shown between the risk groups with respect to infection incidence Yılmaz et al. [5] reported the mean number of neutropenic attacks as 2.6 (1 -7)
in children treated with the ALL BFM 95 protocol between 1995 and 2005. In our study, the mean number of neutropenic attacks was 4.9 ± 1.17 (3 -9) ( Table   4) older protocols, the number of neutropenic attacks appears to be quite small compared to other periods ( Figure 3 ). Since we don't know about the incidence of infection during the HDMTX period, we could not make a comparison; however, we cannot declare that the increase in the number of neutropenic attacks resulted from the difference in the MTX dose. The differences in the infection incidence can be explained by the severity and duration of neutropenia, the dose and the frequency of chemotherapeutics used in the chemotherapy protocols, patient-related factors, environmental conditions and the differences between the durations of hospitalization. Open Access Library Journal
Anemia is an important issue commonly observed in patients with malignity.
Decreased erythrocyte production due to nutritional deficiencies, inadequate response to erythropoietin, tumor infiltration of the bone marrow and inadequate erythrocyte production due to chemotherapy drugs may lead to anemia [22] . Studies report that in patients with Hodgkin lymphoma, treated with ABVD protocol, no grade 3 or higher-grade toxicity (Hb < 8 g/L) developed while it was reported at a rate of 17% -79% in case of non-Hodgkin lymphoma [23] . In our study, the incidence of grade 3 and higher grade toxicity in hemoglobin was between 5% and 34%.
Thrombocytopenia is a side effect of chemotherapeutic drugs. In the USA, based on the data from electronic medical records of 47.159 adult patients with solid tumors, the incidence of grade 3 and higher-grade thrombocytopenia was reported as 10.6% [24] . In a Spanish study about leukemic patients, the incidence of grade 3 and higher-grade thrombocytopenia was 44% and the mean duration of thrombocytopenia was 9 (1 -35) days [17] In our study, the incidence of grade 3 and higher grade thrombocytopenia was between 12% and 51%.
Conclusion
Induction period is the period where the bone marrow is most severely suppressed in leukemic children treated with the ALL IC BFM 2009 protocol. In this period, both the number of febrile neutropenic episodes and the requirement for transfusion is higher than other periods. The most important factor to determine the incidence of febrile neutropenic episodes is the neutropenia duration and the absolute neutrophil count. One should be careful during this period against infections and protective measures need to be increased. Considering the amount of transfusion administered during chemotherapy, studies on the use of erythropoietic and thrombopoietic agents to increase the life quality of patients, and protect against transfusion-related complications would be important.
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